Skip to main content
IMNM logo

IMNM · Immunome Inc. · Executive Compensation

Track IMNM — free
$16.40 -0.38 (-2.26%)
Market Cap
$1.96B
Shares
118.07M
Volume · Nov 19 854.51K Avg daily vol (3M) 1.35M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2023
Executive Total
Clay Siegall $14,866,831
Bob Lechleider $2,915,362
Jack Higgins $1,840,854
Purnanand D. Sarma $1,437,295
Fiscal 2022
Executive Total
Purnanand D. Sarma $990,309
Fiscal 2021
Executive Total
Dennis H. Giesing $3,499,917
Corleen M. Roche $3,096,344
Purnanand D. Sarma $2,111,914
Fiscal 2020
Executive Total
Purnanand D. Sarma $1,695,002
Sandra Stoneman $1,314,397
Michael J. Morin $936,806
Fiscal 2019
Executive Total
Michael J. Morin $363,770
Purnanand D. Sarma $339,910
Sandra Stoneman —

Executive changes

Person Change Filed
Bob Lapetina
“Mr. Lapetina’s resignation is not the result of any disagreement with the Company.”
Resigned 2024-04-30
Sandra Swain, M.D. Appointed 2024-04-25
Carol Schafer Appointed 2024-01-02
Bob Lapetina Appointed 2023-12-29
Max Rosett Appointed 2023-12-29
Jean-Jacques Bienaimé Appointed 2023-11-08
Clay B. Siegall, Ph.D. Appointed 2023-10-04
James Boylan Appointed 2023-10-04
Franklyn Prendergast Appointed 2023-10-04
Bruce Turner Appointed 2023-10-04
Isaac Barchas Appointed 2023-10-04
Corleen Roche Appointed 2023-10-04
Sandra Stoneman Appointed 2023-10-04
Matthew Robinson Appointed 2023-10-04
Clay Siegall Appointed 2023-10-04
Dennis Giesing Terminated 2023-10-04
Jack Higgins Appointed 2023-10-04
Purnanand D. Sarma
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04
Purnanand D. Sarma
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04
Michael Lefenfeld
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04
John LaMattina
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04
Richard Baron
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04
Michael Rapoport
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Resigned 2023-10-04

Leadership

Key facts CIK 1472012 CUSIP 45257U108 13F (30d) 216 filings 203 filers Visit website Investor relations